RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and BRCA2, three closely located genes on chromosome 13q, are frequently deleted in prostate cancer individually or jointly. Loss of RNASEH2B confers cancer cells sensitivity to poly(ADP–ribose) polymerase (PARP) inhibition due to impaired ribonucleotide excision repair and PARP trapping. When co-deleted with RB1, however, cells lose their sensitivity, in part, through E2F1-induced BRCA2 expression, thereby enhancing homologous recombination repair capacity. Nevertheless, loss of BRCA2 re-sensitizes RNASEH2B/RB1 co-deleted cells to PARP inhibition. Our results may explain some of the disparate clinical results from PARP inhibition due to interaction between multiple genomic alterations and support a comprehensive genomic testing to determine who may benefit from PARP inhibition. Finally, we show that ATR inhibition can disrupt E2F1-induced BRCA2 expression and overcome PARP inhibitor resistance caused by RB1 loss.

[1]  K. Knudsen,et al.  RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. , 2021, Cancer discovery.

[2]  S. West,et al.  Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors , 2021, Science.

[3]  J. Gillet.  Faculty Opinions recommendation of The great escape: tumour cell plasticity in resistance to targeted therapy. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[4]  G. Mills,et al.  Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models , 2020, Nature Communications.

[5]  Michael D. Nyquist,et al.  Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. , 2020, Cell reports.

[6]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[7]  T. Aittokallio,et al.  SynergyFinder 2.0: visual analytics of multi-drug combination synergies , 2020, Nucleic Acids Res..

[8]  Y. Kawasawa,et al.  Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens , 2019, Nature Communications.

[9]  P. Kantoff,et al.  Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression , 2019, Clinical Cancer Research.

[10]  N. Tunariu,et al.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[11]  Kejiao Li,et al.  A Genetic Map of the Response to DNA Damage in Human Cells , 2019, Cell.

[12]  F. D. de Sauvage,et al.  The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.

[13]  E. Antonarakis,et al.  Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.

[14]  A. Bryce,et al.  Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses , 2019, Annals of Oncology.

[15]  A. Sboner,et al.  PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer , 2019, Clinical Cancer Research.

[16]  A. Kibel,et al.  Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function , 2019, Proceedings of the National Academy of Sciences.

[17]  M. Loda,et al.  Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.

[18]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[19]  M. Gleave,et al.  Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[20]  B. Leiby,et al.  PARP‐1 regulates DNA repair factor availability , 2018, EMBO molecular medicine.

[21]  F. Demichelis,et al.  RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer , 2018, Clinical Cancer Research.

[22]  G. Sauter,et al.  13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer , 2018, Genes, chromosomes & cancer.

[23]  M. Smolka,et al.  ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells , 2018, Nucleic acids research.

[24]  Martin A. M. Reijns,et al.  CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.

[25]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[26]  M. Rubin,et al.  Differential impact of RB status on E2F1 reprogramming in human cancer , 2017, The Journal of clinical investigation.

[27]  H. Kurumizaka,et al.  RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination. , 2017, Molecular cell.

[28]  Tero Aittokallio,et al.  SynergyFinder: a web application for analyzing drug combination dose–response matrix data , 2017, Bioinform..

[29]  S. Ramaswamy,et al.  ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells , 2017, Genes & development.

[30]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[31]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[32]  N. Dyson.  RB1: a prototype tumor suppressor and an enigma , 2016, Genes & development.

[33]  R. D. de Bruin,et al.  Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage , 2016, Cell reports.

[34]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[35]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[36]  Jessica L. Boisvert,et al.  Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. , 2015, Molecular cell.

[37]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[38]  P. Fortina,et al.  The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness , 2014, Clinical Cancer Research.

[39]  Martin A. M. Reijns,et al.  Ribonuclease H2 in health and disease. , 2014, Biochemical Society transactions.

[40]  S. Vowler,et al.  HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network , 2014, EMBO molecular medicine.

[41]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[42]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[43]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[44]  D. Terrian,et al.  p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3 , 2012, Cell cycle.

[45]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[46]  L. Jia,et al.  Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions , 2012, Nucleic acids research.

[47]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[48]  S. Detti,et al.  Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. , 2012, Clinical genitourinary cancer.

[49]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[50]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[51]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[52]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[53]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[54]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[55]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[56]  C. Simbulan-Rosenthal,et al.  PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase , 2003, Oncogene.

[57]  H. Frierson,et al.  Deletion at 13q21 is associated with aggressive prostate cancers. , 2000, Cancer research.

[58]  J. Nevins,et al.  Role of E2F transcription factor in E1A-mediated trans activation of cellular genes , 1991, Journal of virology.

[59]  David G Johnson,et al.  Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. , 2012, Cancer research.

[60]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[61]  A. Freeman,et al.  Allelic imbalance at 13q14.2 approximately q14.3 in localized prostate cancer is associated with early biochemical relapse. , 2007, Cancer genetics and cytogenetics.

[62]  N. Oppenheimer,et al.  Structure and mechanism , 1989 .